Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Taxus Liberte stent receives CE Mark for use in diabetic patients

Boston Scientific : 24 December, 2007  (New Product)
Boston Scientific’s Taxus Liberte paclitaxel-eluting coronary stent system has received European CE Mark approval for use in patients with diabetes (Ref 1).
Boston Scientific submitted data showing the Taxus Liberte Stent has benefited diabetic patients with coronary artery disease, both in clinical trials and real-world registries.

The approval means the Taxus Liberte Stent system now has more CE Mark-
approved indications than any other drug-eluting stent, allowing treatment of
a wide range of patients including many of those at high risk. The Taxus
Liberte Stent system is the most frequently used drug-eluting Stent system in
Europe.

'Achieving CE Mark approval for Taxus Liberte in patients with diabetes is an important milestone,' said David McFaul, Boston Scientific senior vice president, international. 'As a leader in devices for the treatment of cardiovascular disease, Boston Scientific's goal is to provide patients with the most advanced treatment options available. In this case, we are offering another specific solution for diabetic patients outside the United States, who are typically at higher risk for adverse events compared to non-diabetic patients.'

Combined data from four Taxus Atlas trials supported the efficacy and safety
of the Taxus Liberte Stent system in diabetic patients (Ref 2).

The trials examined 1,529 patients treated with the Taxus Liberte Stent system, 413 of whom had diabetes, and reported similar rates of target lesion revascularisation (TLR, or retreatment), cardiac death, myocardial infarction (MI, or heart attack) and Stent thrombosis (clotting) between diabetic and non-diabetic Stent recipients after adjustment for differences in risk at baseline.

Diabetes affects more than 200 million people worldwide and is expected to affect 360 million people by 2030 (Ref 3). Approximately half of all patients presenting with coronary artery disease (CAD) in Europe have diabetes (Ref 4).

Diabetic patients with CAD often have poorer outcomes after revascularisation procedures because their blood vessels tend to build up more plaque than the vessels of non-diabetic patients, and their CAD advances more quickly. CAD is the most common cause of death among European adults with diabetes (Ref 5).

As a result of the expanded CE Mark, the Taxus Liberte Stent system in the
European Union is indicated for treatment of de novo and restenotic lesions
or total occlusions in patients with coronary artery disease - angina; silent ischemia; acute myocardial infarction - to improve luminal diameter and reduce restenosis within the Stent and at the Stent edges in native coronary arteries. The Taxus Liberte Stent system is also indicated for patients with concomitant diabetes mellitus as well as treatment of abrupt or threatened closure in patients with failed interventional therapy.

The Taxus Liberte Stent is available outside the USA in a wide range of sizes to treat a diversity of vessel sizes and lesion lengths seen in patients with coronary artery disease.

The Taxus Liberte Stent system is pending approval by the US Food and Drug
Administration and is not available for sale in the USA.

Ref 1 - For patients with concomitant diabetes mellitus.

Ref 2 - Ormiston J, Mahmud E, Mandinov L, et al. Taxus Liberte attenuates the risk of restenosis in diabetics: results from the Taxus Atlas Program. Presented at the annual Transcatheter Cardiovascular Therapeutics symposium, Washington, DC, 20-25 October 2007.

Ref 3 - Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.

Ref 4 - Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25(21):1880-90.

Ref 5 - Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88-136.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo